Comparative Pharmacology
Head-to-head clinical analysis: GLIADEL versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLIADEL versus TEPYLUTE.
GLIADEL vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLIADEL (carmustine implant) is a biodegradable wafer that delivers carmustine, a nitrosourea alkylating agent, directly into the tumor resection cavity. Carmustine alkylates DNA and RNA, leading to cross-linking and inhibition of DNA replication, ultimately causing cell death. It is cell cycle phase nonspecific.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
Gliadel (carmustine) implant is administered intraoperatively as 8 wafers, each containing 7.7 mg carmustine, placed in the resection cavity after tumor debulking. Maximum dose is 61.6 mg (8 wafers).
100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 hours for the active dianhydrogalactitol metabolite. Clinical context: short half-life supports local interstitial delivery with minimal systemic accumulation.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Primarily renal (60-70% as unchanged drug and metabolites) and biliary/fecal (15-20%). Approximately 10-15% is eliminated via exhaled air as CO2.
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category C
Category C
Alkylating Agent
Alkylating Agent